Washington [US], June 12 (ANI): A drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy, as demonstrated by researchers at the Ludwig Center at Harvard.
Washington [US], June 9 (ANI): A study conducted by researchers at the Ludwig Center at Harvard has demonstrated how a drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy.
Washington D.C. [USA], April 27 (ANI): In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a